Filing Flows › Arcutis Biotherapeutics (ARQT) › Q4 2025
Arcutis Biotherapeutics (ARQT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 25, 2026
Arcutis Biotherapeutics (ARQT) reported revenue of $130M for the fourth quarter 2025 (Q4 2025), +81% from a year earlier and +31% from the quarter before. Operating margin was 14.2%, net earnings $17.4M (13.4% of revenue).
Arcutis Biotherapeutics, Q4 2025: revenue $130M (+82% year over year), operating margin 14.2%, net earnings $17.4M, operating cash flow $26.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $130M | +31% | +81% |
| Operating profit | $18.4M | +116% | — |
| Net earnings | $17.4M | +135% | — |
| Operating cash flow | $26.2M | — | — |
What changed
Revenue was $129.5M in Q4 2025, up 81% year over year and up 31% from the previous quarter.
Operating profit was $18.4M, a 14.2% margin (up 24.9 points year over year). Total costs grew 41% against revenue growth of 81%. The fastest-growing cost line was Cost of revenue (+69%). Net earnings were $17.4M. The effective tax rate was 2.6%.
Operating cash flow was $26.2M, 151% of net earnings. Non-cash charges added back $10.1M of share-based compensation.
Questions
What was Arcutis Biotherapeutics' revenue in the fourth quarter 2025?
Arcutis Biotherapeutics (ARQT) reported revenue of $130M for the fourth quarter 2025 (Q4 2025), +81% from a year earlier and +31% from the quarter before.
Was Arcutis Biotherapeutics profitable in the fourth quarter 2025?
Operating profit was $18.4M (14.2% of revenue) and net earnings $17.4M.